# First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

> **NCT06667167** · PHASE2 · RECRUITING · sponsor: **Nir Peled** · enrollment: 21 (estimated)

## Conditions studied

- NSCLC (non-small Cell Lung Cancer)

## Interventions

- **DRUG:** Induction Carboplatin

## Key facts

- **NCT ID:** NCT06667167
- **Lead sponsor:** Nir Peled
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06667167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06667167, "First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06667167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*